Literature DB >> 12373268

Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma.

Robert I Ketchell1, Marianne W Jensen, Philip Lumley, Andrew M Wright, Mark I Allenby, Brian J O'connor.   

Abstract

Inhaled adenosine 5'-monophosphate (AMP) has an "indirect" bronchoconstrictive effect through mast cell degranulation and mediator release, whereas inhaled histamine has a "direct" effect on smooth muscle. Prolonged treatment with inhaled glucocorticosteroids attenuates airway responsiveness (AR) to AMP and histamine. We investigated the early effects of inhaled fluticasone propionate (FP) therapy on AR in 3 consecutive double-blind, randomized, placebo-controlled crossover studies in steroid-naive subjects with mild asthma. In one study, each of 12 subjects received FP 1000 microg or matched placebo for 7 inhalations at 12 hourly intervals; AR to AMP and FEV(1) were measured 2 hours after the 3rd and 7th inhalations. In a second study, each of 12 subjects received FP 100, 250, or 1000 microg or matched placebo for 3 inhalations at 12 hourly intervals; AR to AMP and FEV(1) were measured 2 hours after the 1st and 3rd inhalations. In a third study, each of 8 subjects received a single inhalation of FP 1000 microg or matched placebo; AR to histamine was measured 2 hours later. In the first study, FP 1000 microg significantly attenuated AR to AMP by 2.7 and 2.5 doubling doses after 3 and 7 inhalations, respectively (P < or =.0001). In the second study, FP 100, 250, and 1000 microg significantly attenuated AR to AMP by 1.9, 2.2, and 2.7 doubling doses, respectively, after 1 inhalation and by 2.4, 2.2, and 3.2 doubling doses, respectively, after 3 inhalations (P < or =.0001); a small but significant increase in FEV(1) (>0.15 L) was observed after 3 inhalations but not after 1 inhalation of FP irrespective of dose (P < or =.05). In the third study, a single inhalation of FP 1000 microg had no effect on AR to histamine. We have demonstrated a reduction in AR to AMP but not AR to histamine within 2 hours of a single inhalation of FP. This reflects a rapid, topical anti-inflammatory action of inhaled FP by a mechanism of action that remains unknown.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373268     DOI: 10.1067/mai.2002.128486

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  20 in total

Review 1.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

Review 2.  Glucocorticosteroids: current and future directions.

Authors:  Peter J Barnes
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Mast cell involvement in the adenosine mediated airway hyper-reactivity in a murine model of ovalbumin-induced lung inflammation.

Authors:  Daniel Wyss; Olivier Bonneau; Alexandre Trifilieff
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

4.  Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.

Authors:  René Aalbers; Martin Boorsma; Hanneke J van der Woude; René E Jonkers
Journal:  Respir Res       Date:  2010-05-28

Review 5.  Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma.

Authors:  Carlos E Rodriguez-Martinez; Gustavo Nino; Jose A Castro-Rodriguez
Journal:  Pediatr Pulmonol       Date:  2014-06-25

6.  The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naive asthmatics.

Authors:  Dave Singh; Jennifer Fairwood; Robert Murdoch; Amanda Weeks; Paul Russell; Kay Roy; Steve Langley; Ashley Woodcock
Journal:  Br J Clin Pharmacol       Date:  2008-05-27       Impact factor: 4.335

7.  Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen.

Authors:  Bruno Tigani; Jason P Hannon; Elisabeth Schaeublin; Lazzaro Mazzoni; John R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-06-24       Impact factor: 3.000

8.  Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol.

Authors:  D l Turner; N Ferrari; W R Ford; E J Kidd; B Nevin; L Paquet; P Renzi; K J Broadley
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

9.  Genomic and non-genomic actions of glucocorticoids in asthma.

Authors:  Abdullah A Alangari
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

10.  Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.

Authors:  Anna Bodzenta-Lukaszyk; Andrzej Dymek; Kirsten McAulay; Heikki Mansikka
Journal:  BMC Pulm Med       Date:  2011-05-23       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.